Hypothesis: How do JAK2-inhibitors work in myelofibrosis

Ruben Mesa; Robert Peter Gale

doi:10.1016/j.leukres.2009.04.011

Hypothesis: How do JAK2-inhibitors work in myelofibrosis

Ruben Mesa, Robert Peter Gale

Hematology/Oncology

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

Original language	English (US)
Pages (from-to)	1156-1157
Number of pages	2
Journal	Leukemia Research
Volume	33
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2009.04.011
State	Published - Sep 2009

Keywords

JAK2
JAK2-inhibitors
Myelofibrosis
Myeloproliferative disorders
Myeloproliferative neoplasms

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2009.04.011

Cite this

@article{a4efe7327dcf42358ae5b89a77956d4e,

title = "Hypothesis: How do JAK2-inhibitors work in myelofibrosis",

abstract = "JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.",

keywords = "JAK2, JAK2-inhibitors, Myelofibrosis, Myeloproliferative disorders, Myeloproliferative neoplasms",

author = "Ruben Mesa and Gale, {Robert Peter}",

year = "2009",

month = sep,

doi = "10.1016/j.leukres.2009.04.011",

language = "English (US)",

volume = "33",

pages = "1156--1157",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Hypothesis

T2 - How do JAK2-inhibitors work in myelofibrosis

AU - Mesa, Ruben

AU - Gale, Robert Peter

PY - 2009/9

Y1 - 2009/9

N2 - JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

AB - JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

KW - JAK2

KW - JAK2-inhibitors

KW - Myelofibrosis

KW - Myeloproliferative disorders

KW - Myeloproliferative neoplasms

UR - http://www.scopus.com/inward/record.url?scp=67549114832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549114832&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.04.011

DO - 10.1016/j.leukres.2009.04.011

M3 - Comment/debate

C2 - 19450878

AN - SCOPUS:67549114832

SN - 0145-2126

VL - 33

SP - 1156

EP - 1157

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Hypothesis: How do JAK2-inhibitors work in myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this